Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas

Completed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy, such as alanosine, use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of alanosine in treating patients with high-grade progressive or recurrent malignant gliomas.

Key facts

Study ID

NCT00075894

Run by

National Cancer Institute (NCI)

People needed

18

Starts

2004-03-01

Last updated by the study team

2009-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• H. Lee Moffitt Cancer Center and Research Institute at University of South Florida — Tampa, Florida, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Josephine Ford Cancer Center at Henry Ford Hospital — Detroit, Michigan, United States
• Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.